0 XP   0   0   0

Genomma Lab Internacional S.A.B. de C.V
Buy, Hold or Sell?

Should you buy, hold or sell Genomma Lab Internacional S.A.B. de C.V?

I guess you are interested in Genomma Lab Internacional S.A.B. de C.V. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Genomma Lab Internacional S.A.B. de C.V

Let's start. I'm going to help you getting a better view of Genomma Lab Internacional S.A.B. de C.V. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Genomma Lab Internacional S.A.B. de C.V even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Genomma Lab Internacional S.A.B. de C.V is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Genomma Lab Internacional S.A.B. de C.V. The closing price on 2023-02-03 was ₱19.01 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Genomma Lab Internacional S.A.B. de C.V Daily Candlestick Chart
Genomma Lab Internacional S.A.B. de C.V Daily Candlestick Chart
Summary









1. Valuation of Genomma Lab Internacional S.A.B. de C.V




Current price per share

₱19.01

2. Growth of Genomma Lab Internacional S.A.B. de C.V




Is Genomma Lab Internacional S.A.B. de C.V growing?

Current yearPrevious yearGrowGrow %
How rich?$575.5m$529.9m$25.3m4.6%

How much money is Genomma Lab Internacional S.A.B. de C.V making?

Current yearPrevious yearGrowGrow %
Making money$17.9m$18.6m-$782.1k-4.4%
Net Profit Margin8.1%9.5%--

How much money comes from the company's main activities?

3. Financial Health of Genomma Lab Internacional S.A.B. de C.V




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings (Drug Manufacturers-Specialty & Generic)  


Richest
#115 / 705

Most Revenue
#126 / 705

Most Profit
#124 / 705

Most Efficient
#227 / 705


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Genomma Lab Internacional S.A.B. de C.V.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genomma Lab Internacional S.A.B. de C.V earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 9.2% means that $0.09 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 9.2%. The company is making a profit. +1
  • The TTM is 8.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.2%TTM8.1%+1.1%
TTM8.1%YOY9.5%-1.5%
TTM8.1%5Y8.8%-0.8%
5Y8.8%10Y9.9%-1.1%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2%0.4%+8.8%
TTM8.1%0.3%+7.8%
YOY9.5%0.2%+9.3%
5Y8.8%-0.7%+9.5%
10Y9.9%-0.1%+10.0%
1.1.2. Return on Assets

Shows how efficient Genomma Lab Internacional S.A.B. de C.V is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • 1.8% Return on Assets means that Genomma Lab Internacional S.A.B. de C.V generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.6%+0.3%
TTM1.6%YOY1.6%0.0%
TTM1.6%5Y1.5%+0.0%
5Y1.5%10Y1.8%-0.2%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%0.1%+1.7%
TTM1.6%0.1%+1.5%
YOY1.6%-0.1%+1.7%
5Y1.5%-0.2%+1.7%
10Y1.8%0.1%+1.7%
1.1.3. Return on Equity

Shows how efficient Genomma Lab Internacional S.A.B. de C.V is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • 3.7% Return on Equity means Genomma Lab Internacional S.A.B. de C.V generated $0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 3.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.2%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.7%TTM3.2%+0.5%
TTM3.2%YOY3.5%-0.3%
TTM3.2%5Y3.5%-0.3%
5Y3.5%10Y3.8%-0.4%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7%0.6%+3.1%
TTM3.2%0.4%+2.8%
YOY3.5%0.4%+3.1%
5Y3.5%-0.3%+3.8%
10Y3.8%0.1%+3.7%

1.2. Operating Efficiency of Genomma Lab Internacional S.A.B. de C.V.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genomma Lab Internacional S.A.B. de C.V is operating .

  • Measures how much profit Genomma Lab Internacional S.A.B. de C.V makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 19.8% means the company generated $0.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 19.8%. The company is operating efficient. +1
  • The TTM is 19.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ19.8%TTM19.8%0.0%
TTM19.8%YOY19.5%+0.3%
TTM19.8%5Y19.9%-0.1%
5Y19.9%10Y12.0%+7.9%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ19.8%2.5%+17.3%
TTM19.8%1.6%+18.2%
YOY19.5%2.7%+16.8%
5Y19.9%1.8%+18.1%
10Y12.0%0.8%+11.2%
1.2.2. Operating Ratio

Measures how efficient Genomma Lab Internacional S.A.B. de C.V is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 1.18 means that the operating costs are $1.18 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.185. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.190. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.185TTM1.190-0.006
TTM1.190YOY1.179+0.011
TTM1.1905Y1.170+0.020
5Y1.17010Y0.814+0.356
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1851.473-0.288
TTM1.1901.456-0.266
YOY1.1791.398-0.219
5Y1.1701.374-0.204
10Y0.8141.191-0.377

1.3. Liquidity of Genomma Lab Internacional S.A.B. de C.V.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.24 means the company has $1.24 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 1.244. The company is just able to pay all its short-term debts.
  • The TTM is 1.601. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.244TTM1.601-0.357
TTM1.601YOY1.774-0.173
TTM1.6015Y1.734-0.133
5Y1.73410Y1.016+0.717
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2441.880-0.636
TTM1.6011.901-0.300
YOY1.7742.112-0.338
5Y1.7342.182-0.448
10Y1.0161.891-0.875
1.3.2. Quick Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.73 means the company can pay off $0.73 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.725. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.980. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.725TTM0.980-0.254
TTM0.980YOY1.093-0.113
TTM0.9805Y0.990-0.011
5Y0.99010Y1.220-0.230
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7250.733-0.008
TTM0.9800.796+0.184
YOY1.0930.808+0.285
5Y0.9900.834+0.156
10Y1.2200.821+0.399

1.4. Solvency of Genomma Lab Internacional S.A.B. de C.V.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genomma Lab Internacional S.A.B. de C.V assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.50 means that Genomma Lab Internacional S.A.B. de C.V assets are financed with 50.0% credit (debt) and the remaining percentage (100% - 50.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.500. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.519. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.500TTM0.519-0.019
TTM0.519YOY0.558-0.039
TTM0.5195Y0.562-0.043
5Y0.56210Y0.538+0.024
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5000.437+0.063
TTM0.5190.424+0.095
YOY0.5580.398+0.160
5Y0.5620.398+0.164
10Y0.5380.401+0.137
1.4.2. Debt to Equity Ratio

Measures if Genomma Lab Internacional S.A.B. de C.V is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 99.9% means that company has $1.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 0.999. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.079. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.999TTM1.079-0.080
TTM1.079YOY1.261-0.182
TTM1.0795Y1.291-0.212
5Y1.29110Y1.201+0.090
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9990.652+0.347
TTM1.0790.675+0.404
YOY1.2610.623+0.638
5Y1.2910.684+0.607
10Y1.2010.697+0.504

2. Market Valuation of Genomma Lab Internacional S.A.B. de C.V

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genomma Lab Internacional S.A.B. de C.V generates.

  • Above 15 is considered overpriced but always compare Genomma Lab Internacional S.A.B. de C.V to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of 34.93 means the investor is paying $34.93 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 47.775. Good. +1
  • The MRQ is 34.933. Good. +1
  • The TTM is 62.311. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD47.775MRQ34.933+12.842
MRQ34.933TTM62.311-27.379
TTM62.311YOY57.565+4.746
TTM62.3115Y84.847-22.536
5Y84.84710Y111.201-26.354
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD47.775-0.124+47.899
MRQ34.933-0.437+35.370
TTM62.311-0.102+62.413
YOY57.56515.340+42.225
5Y84.8477.916+76.931
10Y111.2017.700+103.501
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Genomma Lab Internacional S.A.B. de C.V.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The MRQ is 35.411. Seems overpriced? -1
  • The TTM is 74.357. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ35.411TTM74.357-38.946
TTM74.357YOY59.013+15.344
TTM74.3575Y235.076-160.719
5Y235.07610Y1,088.600-853.523
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ35.4110.012+35.399
TTM74.3570.010+74.347
YOY59.0130.004+59.009
5Y235.0760.010+235.066
10Y1,088.6000.021+1,088.579

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genomma Lab Internacional S.A.B. de C.V is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 1.28 means the investor is paying $1.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genomma Lab Internacional S.A.B. de C.V:

  • The EOD is 1.747. Good. +1
  • The MRQ is 1.277. Good. +1
  • The TTM is 1.851. Good. +1
Trends
Current periodCompared to+/- 
EOD1.747MRQ1.277+0.470
MRQ1.277TTM1.851-0.574
TTM1.851YOY2.016-0.165
TTM1.8515Y2.160-0.309
5Y2.16010Y2.547-0.387
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD1.7471.415+0.332
MRQ1.2771.586-0.309
TTM1.8512.019-0.168
YOY2.0162.230-0.214
5Y2.1601.895+0.265
10Y2.5471.505+1.042
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genomma Lab Internacional S.A.B. de C.V compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1420.118+20%0.311-54%0.215-34%0.116+23%
Book Value Growth--1.0131.008+1%1.032-2%1.026-1%1.0170%
Book Value Per Share--10.88310.502+4%9.881+10%8.786+24%8.648+26%
Book Value Per Share Growth--1.0131.012+0%1.032-2%1.026-1%1.0160%
Current Ratio--1.2441.601-22%1.774-30%1.734-28%1.016+22%
Debt To Asset Ratio--0.5000.519-4%0.558-10%0.562-11%0.538-7%
Debt To Equity Ratio--0.9991.079-7%1.261-21%1.291-23%1.201-17%
Dividend Per Share---0.293-100%0.289-100%0.116-100%0.058-100%
Dividend Per Share Growth---0.754-100%1.000-100%0.836-100%0.836-100%
Eps--0.3980.339+17%0.348+14%0.303+31%0.318+25%
Eps Growth--0.9861.077-8%1.000-1%1.448-32%1.879-48%
Free Cash Flow Per Share--0.3080.610-50%0.365-16%0.292+5%0.551-44%
Free Cash Flow Per Share Growth--1.5241.299+17%2.819-46%1.975-23%1.778-14%
Free Cash Flow To Equity Per Share---0.256-0.012-95%0.235-209%0.122-309%0.548-147%
Free Cash Flow To Equity Per Share Growth--0.8680.700+24%1.565-45%-0.155+118%0.589+47%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--23.969--------
Intrinsic Value_10Y_min---1.370--------
Intrinsic Value_1Y_max--2.437--------
Intrinsic Value_1Y_min--1.170--------
Intrinsic Value_3Y_max--7.296--------
Intrinsic Value_3Y_min--2.403--------
Intrinsic Value_5Y_max--12.123--------
Intrinsic Value_5Y_min--2.410--------
Net Profit Margin--0.0920.081+14%0.095-4%0.088+4%0.099-8%
Operating Margin--0.1980.1980%0.195+2%0.199-1%0.120+64%
Operating Ratio--1.1851.1900%1.179+0%1.170+1%0.814+45%
Pb Ratio1.747+27%1.2771.851-31%2.016-37%2.160-41%2.547-50%
Pe Ratio47.775+27%34.93362.311-44%57.565-39%84.847-59%111.201-69%
Peg Ratio--35.41174.357-52%59.013-40%235.076-85%1088.600-97%
Price Per Share19.010+27%13.90019.340-28%19.903-30%18.742-26%21.343-35%
Price To Total Gains Ratio133.566+27%97.663333.508-71%37.991+157%86.333+13%70.881+38%
Profit Growth--0.9861.075-8%1.000-1%1.461-32%1.886-48%
Quick Ratio--0.7250.980-26%1.093-34%0.990-27%1.220-41%
Return On Assets--0.0180.016+18%0.016+17%0.015+21%0.018+4%
Return On Equity--0.0370.032+14%0.035+4%0.035+6%0.038-4%
Revenue Growth--1.0061.023-2%1.039-3%1.019-1%1.028-2%
Total Gains Per Share--0.1420.412-65%0.599-76%0.332-57%0.174-18%
Total Gains Per Share Growth--0.1819.931-98%1.292-86%3.167-94%1.470-88%
Usd Book Value--575530534.100555358462.875+4%529959513.425+9%468622723.860+23%459327030.148+25%
Usd Book Value Change Per Share--0.0080.006+20%0.016-54%0.011-34%0.006+23%
Usd Book Value Per Share--0.5740.553+4%0.521+10%0.463+24%0.456+26%
Usd Dividend Per Share---0.015-100%0.015-100%0.006-100%0.003-100%
Usd Eps--0.0210.018+17%0.018+14%0.016+31%0.017+25%
Usd Free Cash Flow--16269596.70032250924.400-50%19575375.475-17%11665830.100+39%5832915.050+179%
Usd Free Cash Flow Per Share--0.0160.032-50%0.019-16%0.015+5%0.029-44%
Usd Free Cash Flow To Equity Per Share---0.013-0.001-95%0.012-209%0.006-309%0.029-147%
Usd Price Per Share1.002+27%0.7331.019-28%1.049-30%0.988-26%1.125-35%
Usd Profit--21041845.20017908145.100+17%18690252.625+13%16163137.430+30%16913710.593+24%
Usd Revenue--229204737.200221047488.650+4%195890116.000+17%183223144.000+25%170571029.448+34%
Usd Total Gains Per Share--0.0080.022-65%0.032-76%0.017-57%0.009-18%
 EOD+2 -3MRQTTM+23 -19YOY+17 -255Y+21 -2110Y+22 -21

3.2. Fundamental Score

Let's check the fundamental score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1547.775
Price to Book Ratio (EOD)Between0-11.747
Net Profit Margin (MRQ)Greater than00.092
Operating Margin (MRQ)Greater than00.198
Quick Ratio (MRQ)Greater than10.725
Current Ratio (MRQ)Greater than11.244
Debt to Asset Ratio (MRQ)Less than10.500
Debt to Equity Ratio (MRQ)Less than10.999
Return on Equity (MRQ)Greater than0.150.037
Return on Assets (MRQ)Greater than0.050.018
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Genomma Lab Internacional S.A.B. de C.V based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.725
Ma 20Greater thanMa 5017.680
Ma 50Greater thanMa 10017.221
Ma 100Greater thanMa 20015.918
OpenGreater thanClose18.930
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in MXN. All numbers in thousands.

Summary
Total Assets21,827,930
Total Liabilities10,907,047
Total Stockholder Equity10,920,883
 As reported
Total Liabilities 10,907,047
Total Stockholder Equity+ 10,920,883
Total Assets = 21,827,930

Assets

Total Assets21,827,930
Total Current Assets11,585,537
Long-term Assets11,585,537
Total Current Assets
Cash And Cash Equivalents 1,093,330
Net Receivables 6,757,263
Inventory 2,858,866
Other Current Assets 876,078
Total Current Assets  (as reported)11,585,537
Total Current Assets  (calculated)11,585,537
+/-0
Long-term Assets
Property Plant Equipment 3,499,200
Intangible Assets 5,030,610
Other Assets 711,785
Long-term Assets  (as reported)10,242,393
Long-term Assets  (calculated)9,241,595
+/- 1,000,798

Liabilities & Shareholders' Equity

Total Current Liabilities9,314,740
Long-term Liabilities1,592,307
Total Stockholder Equity10,920,883
Total Current Liabilities
Short Long Term Debt 4,138,224
Accounts payable 2,095,397
Other Current Liabilities 2,898,829
Total Current Liabilities  (as reported)9,314,740
Total Current Liabilities  (calculated)9,132,450
+/- 182,290
Long-term Liabilities
Long term Debt 970,855
Other Liabilities 583,718
Long-term Liabilities  (as reported)1,592,307
Long-term Liabilities  (calculated)1,554,573
+/- 37,734
Total Stockholder Equity
Common Stock1,912,967
Retained Earnings 9,963,318
Total Stockholder Equity (as reported)10,920,883
Total Stockholder Equity (calculated)11,876,285
+/- 955,402
Other
Capital Stock1,912,967
Common Stock Shares Outstanding 1,003,437
Net Debt 4,015,749
Net Invested Capital 16,029,962
Net Tangible Assets 5,606,603
Net Working Capital 2,270,797



Balance Sheet

Currency in MXN. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-03-312006-12-312005-12-31
> Total Assets 
475,694
734,614
0
1,194,030
0
2,503,613
2,695,824
2,839,928
2,881,319
3,294,216
3,755,947
4,241,650
4,370,461
4,594,557
5,150,362
5,830,909
6,846,851
7,338,810
8,123,014
9,193,972
8,873,330
10,532,531
11,716,573
12,992,590
13,127,881
13,890,790
15,058,077
17,352,868
17,465,890
18,318,487
18,594,890
25,428,315
25,241,294
24,765,165
20,532,381
17,633,159
17,700,718
17,712,301
15,282,804
15,708,616
16,025,740
16,142,468
15,867,312
15,885,706
17,697,999
16,742,413
17,306,143
18,077,257
18,885,635
19,412,322
19,105,562
19,254,750
20,906,447
21,101,766
21,781,793
22,132,616
22,654,170
22,869,778
23,230,903
21,542,960
22,163,844
22,014,252
21,827,930
21,827,93022,014,25222,163,84421,542,96023,230,90322,869,77822,654,17022,132,61621,781,79321,101,76620,906,44719,254,75019,105,56219,412,32218,885,63518,077,25717,306,14316,742,41317,697,99915,885,70615,867,31216,142,46816,025,74015,708,61615,282,80417,712,30117,700,71817,633,15920,532,38124,765,16525,241,29425,428,31518,594,89018,318,48717,465,89017,352,86815,058,07713,890,79013,127,88112,992,59011,716,57310,532,5318,873,3309,193,9728,123,0147,338,8106,846,8515,830,9095,150,3624,594,5574,370,4614,241,6503,755,9473,294,2162,881,3192,839,9282,695,8242,503,61301,194,0300734,614475,694
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,818,155
0
8,227,055
8,276,515
8,090,105
7,840,639
9,598,847
8,526,818
8,726,891
8,997,564
9,487,324
10,479,717
9,926,178
9,817,549
11,276,493
11,322,984
11,778,894
12,037,474
12,331,554
12,381,463
12,686,939
11,521,057
12,106,509
11,803,847
11,585,537
11,585,53711,803,84712,106,50911,521,05712,686,93912,381,46312,331,55412,037,47411,778,89411,322,98411,276,4939,817,5499,926,17810,479,7179,487,3248,997,5648,726,8918,526,8189,598,8477,840,6398,090,1058,276,5158,227,05507,818,15500000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,591,522
0
1,863,585
1,874,429
1,025,684
1,069,535
2,421,105
1,187,030
1,128,873
1,391,372
1,378,325
1,191,741
1,109,941
899,662
1,346,819
1,186,239
1,567,634
2,048,785
1,824,276
1,408,994
1,755,220
1,220,905
1,553,561
1,299,392
1,093,330
1,093,3301,299,3921,553,5611,220,9051,755,2201,408,9941,824,2762,048,7851,567,6341,186,2391,346,819899,6621,109,9411,191,7411,378,3251,391,3721,128,8731,187,0302,421,1051,069,5351,025,6841,874,4291,863,58501,591,52200000000000000000000000000000000000000
       Net Receivables 
250,586
484,893
0
669,005
0
836,609
1,031,746
766,995
891,033
769,974
1,298,452
1,576,442
1,667,488
1,972,440
2,340,912
2,209,635
2,311,473
2,943,802
2,509,219
3,655,160
4,084,107
4,142,061
4,580,362
5,266,837
4,919,382
4,583,609
4,996,055
5,693,555
5,470,983
6,006,698
6,517,227
5,471,405
4,687,240
4,683,666
5,178,353
3,919,520
3,988,690
3,907,208
4,270,795
4,361,897
4,670,309
4,592,864
5,158,942
5,005,618
5,386,113
5,270,221
5,264,267
5,319,176
3,186,979
3,469,504
3,314,220
6,305,406
6,969,308
7,128,254
6,977,408
7,310,878
7,503,998
7,805,738
7,845,310
7,399,912
7,450,788
7,049,126
6,757,263
6,757,2637,049,1267,450,7887,399,9127,845,3107,805,7387,503,9987,310,8786,977,4087,128,2546,969,3086,305,4063,314,2203,469,5043,186,9795,319,1765,264,2675,270,2215,386,1135,005,6185,158,9424,592,8644,670,3094,361,8974,270,7953,907,2083,988,6903,919,5205,178,3534,683,6664,687,2405,471,4056,517,2276,006,6985,470,9835,693,5554,996,0554,583,6094,919,3825,266,8374,580,3624,142,0614,084,1073,655,1602,509,2192,943,8022,311,4732,209,6352,340,9121,972,4401,667,4881,576,4421,298,452769,974891,033766,9951,031,746836,6090669,0050484,893250,586
       Other Current Assets 
31,411
15,048
0
42,807
0
32,908
49,623
127,394
53,668
102,439
72,526
85,404
95,743
66,226
83,440
73,308
290,198
209,841
206,525
333,885
181,157
319,163
451,653
999,261
1,143,582
1,137,551
866,904
1,084,498
1,130,145
1,218,874
1,195,742
8,889,496
8,845,880
8,589,151
1,969,325
734,665
799,070
1,269,544
763,474
416,199
592,599
582,455
545,172
478,069
666,395
871,127
843,591
589,984
416,092
954,453
620,686
704,638
863,667
792,025
734,982
631,828
666,882
657,064
644,681
698,368
682,142
938,171
876,078
876,078938,171682,142698,368644,681657,064666,882631,828734,982792,025863,667704,638620,686954,453416,092589,984843,591871,127666,395478,069545,172582,455592,599416,199763,4741,269,544799,070734,6651,969,3258,589,1518,845,8808,889,4961,195,7421,218,8741,130,1451,084,498866,9041,137,5511,143,582999,261451,653319,163181,157333,885206,525209,841290,19873,30883,44066,22695,74385,40472,526102,43953,668127,39449,62332,908042,807015,04831,411
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,398,311
8,932,605
9,179,384
9,437,201
9,629,954
9,778,782
9,902,899
10,095,142
10,322,616
10,488,315
10,543,964
10,021,903
10,057,335
10,210,405
10,242,393
10,242,39310,210,40510,057,33510,021,90310,543,96410,488,31510,322,61610,095,1429,902,8999,778,7829,629,9549,437,2019,179,3848,932,6059,398,311000000000000000000000000000000000000000000000000
       Property Plant Equipment 
25,004
25,231
0
44,298
0
65,535
99,560
107,718
107,949
138,613
163,245
260,698
396,934
385,176
407,072
424,996
423,989
429,144
436,958
427,763
430,455
422,478
439,041
403,588
395,866
392,699
387,104
408,383
432,344
431,622
441,888
457,659
423,645
407,078
407,291
406,645
379,684
325,154
324,145
412,811
364,293
369,640
356,500
548,649
647,082
859,024
1,149,171
1,870,234
2,169,829
1,837,787
2,139,073
2,220,748
2,323,961
2,467,356
2,583,429
2,852,165
3,006,415
3,121,197
3,244,776
3,366,118
3,423,790
3,473,626
3,499,200
3,499,2003,473,6263,423,7903,366,1183,244,7763,121,1973,006,4152,852,1652,583,4292,467,3562,323,9612,220,7482,139,0731,837,7872,169,8291,870,2341,149,171859,024647,082548,649356,500369,640364,293412,811324,145325,154379,684406,645407,291407,078423,645457,659441,888431,622432,344408,383387,104392,699395,866403,588439,041422,478430,455427,763436,958429,144423,989424,996407,072385,176396,934260,698163,245138,613107,949107,71899,56065,535044,298025,23125,004
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,998
44,998
44,998
0
44,998
51,950
51,950
0
51,950
51,950
155,293
51,950
51,950
51,950
51,950
52,367
0
0
0
0
0
0
0
0
0
0
0
0000000000052,36751,95051,95051,95051,950155,29351,95051,950051,95051,95044,998044,99844,99844,998000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,382,470
0
1,432,839
1,434,572
1,437,498
1,472,805
1,483,581
1,488,900
1,525,846
1,555,834
1,565,996
1,585,698
1,582,108
1,600,702
0
0
0
0
0
0
0
0
0
0
0
000000000001,600,7021,582,1081,585,6981,565,9961,555,8341,525,8461,488,9001,483,5811,472,8051,437,4981,434,5721,432,83901,382,47000000000000000000000000000000000000000
       Intangible Assets 
5,621
6,479
0
68,210
0
69,422
78,704
80,523
80,517
435,510
435,510
530,780
454,573
577,335
575,151
659,119
1,626,585
1,630,964
1,810,079
2,076,054
2,095,715
2,967,027
3,533,342
3,469,454
3,870,897
4,186,938
4,828,386
4,716,070
6,498,757
6,508,483
6,573,104
5,261,790
7,100,107
7,118,555
7,188,116
5,402,398
6,470,529
6,556,998
5,407,612
5,066,100
5,259,590
5,229,616
5,245,906
5,117,137
5,198,114
5,250,112
5,226,909
4,934,397
4,821,824
4,823,098
4,747,335
4,913,215
4,937,800
4,922,788
4,901,213
4,908,365
4,884,118
4,897,089
4,952,167
5,169,138
4,986,706
5,017,837
5,030,610
5,030,6105,017,8374,986,7065,169,1384,952,1674,897,0894,884,1184,908,3654,901,2134,922,7884,937,8004,913,2154,747,3354,823,0984,821,8244,934,3975,226,9095,250,1125,198,1145,117,1375,245,9065,229,6165,259,5905,066,1005,407,6126,556,9986,470,5295,402,3987,188,1167,118,5557,100,1075,261,7906,573,1046,508,4836,498,7574,716,0704,828,3864,186,9383,870,8973,469,4543,533,3422,967,0272,095,7152,076,0541,810,0791,630,9641,626,585659,119575,151577,335454,573530,780435,510435,51080,51780,52378,70469,422068,21006,4795,621
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,870
8,932,605
9,179,384
92,075
9,629,954
0
0
93,515
0
0
0
220,885
0
0
0
000220,88500093,515009,629,95492,0759,179,3848,932,60566,870000000000000000000000000000000000000000000000000
> Total Liabilities 
310,768
388,542
0
606,590
0
615,864
614,323
527,789
497,932
819,007
1,080,912
1,190,916
1,223,788
1,206,698
1,504,438
1,719,266
2,610,840
2,854,793
3,177,801
3,621,072
3,231,327
4,739,672
5,439,980
5,973,766
6,008,692
6,377,978
7,068,874
8,517,424
8,459,808
8,991,557
9,116,106
14,925,208
14,689,648
13,898,186
9,486,402
8,384,509
8,320,380
8,238,945
8,465,860
8,915,718
9,115,149
9,829,759
9,267,896
8,837,038
10,453,504
9,060,601
9,709,919
10,649,437
11,282,418
11,491,121
11,088,194
11,280,642
12,222,997
12,162,510
12,451,052
12,498,429
12,793,422
12,734,885
12,636,100
11,470,734
11,782,575
11,236,185
10,907,047
10,907,04711,236,18511,782,57511,470,73412,636,10012,734,88512,793,42212,498,42912,451,05212,162,51012,222,99711,280,64211,088,19411,491,12111,282,41810,649,4379,709,9199,060,60110,453,5048,837,0389,267,8969,829,7599,115,1498,915,7188,465,8608,238,9458,320,3808,384,5099,486,40213,898,18614,689,64814,925,2089,116,1068,991,5578,459,8088,517,4247,068,8746,377,9786,008,6925,973,7665,439,9804,739,6723,231,3273,621,0723,177,8012,854,7932,610,8401,719,2661,504,4381,206,6981,223,7881,190,9161,080,912819,007497,932527,789614,323615,8640606,5900388,542310,768
   > Total Current Liabilities 
297,848
366,518
0
579,183
0
607,352
605,428
523,024
492,288
654,329
915,355
1,029,329
1,087,100
1,073,540
1,399,693
1,547,746
2,203,733
1,582,463
1,947,808
2,185,524
1,798,294
2,097,264
2,070,720
2,629,900
3,195,840
3,253,416
2,398,219
3,154,086
2,443,414
2,456,608
2,664,198
7,595,888
6,932,988
6,170,895
2,958,714
2,496,069
2,449,775
2,384,265
4,573,545
5,100,403
5,321,796
5,456,035
6,720,078
6,305,022
5,509,600
3,651,594
3,596,934
4,485,318
6,283,204
6,304,192
5,472,886
5,678,539
6,614,317
9,225,414
6,646,737
6,613,971
7,021,927
7,097,036
7,145,307
6,571,141
6,974,629
7,060,830
9,314,740
9,314,7407,060,8306,974,6296,571,1417,145,3077,097,0367,021,9276,613,9716,646,7379,225,4146,614,3175,678,5395,472,8866,304,1926,283,2044,485,3183,596,9343,651,5945,509,6006,305,0226,720,0785,456,0355,321,7965,100,4034,573,5452,384,2652,449,7752,496,0692,958,7146,170,8956,932,9887,595,8882,664,1982,456,6082,443,4143,154,0862,398,2193,253,4163,195,8402,629,9002,070,7202,097,2641,798,2942,185,5241,947,8081,582,4632,203,7331,547,7461,399,6931,073,5401,087,1001,029,329915,355654,329492,288523,024605,428607,3520579,1830366,518297,848
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
507,576
1,952,456
0
0
0
0
0
0
0
0
0
0
00000000001,952,456507,5761,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,881,854
0
5,817,037
5,798,999
3,201,451
2,073,055
742,461
426,022
85,428
676,022
1,992,042
2,150,196
1,336,062
1,550,006
1,952,456
4,479,627
1,873,827
1,970,239
2,048,127
2,064,651
2,331,623
2,072,309
1,702,726
0
4,138,224
4,138,22401,702,7262,072,3092,331,6232,064,6512,048,1271,970,2391,873,8274,479,6271,952,4561,550,0061,336,0622,150,1961,992,042676,02285,428426,022742,4612,073,0553,201,4515,798,9995,817,03705,881,85400000000000000000000000000000000000000
       Accounts payable 
161,090
114,262
0
78,859
0
261,232
288,363
377,298
307,930
411,192
564,616
594,360
585,132
606,339
723,311
969,099
1,017,730
823,824
833,303
1,262,328
828,342
1,213,283
1,064,676
1,218,663
1,038,471
1,222,130
1,517,129
1,644,125
1,390,111
1,441,339
1,490,297
1,554,690
1,160,518
1,037,835
1,100,611
670,116
685,237
884,912
1,061,085
1,033,545
934,436
1,047,279
1,290,817
1,098,471
1,169,527
1,258,836
1,534,980
1,774,441
2,007,226
1,946,071
1,971,691
1,881,177
1,714,008
1,861,594
1,749,172
1,644,766
1,972,666
2,039,209
1,781,774
1,439,640
1,796,439
1,977,589
2,095,397
2,095,3971,977,5891,796,4391,439,6401,781,7742,039,2091,972,6661,644,7661,749,1721,861,5941,714,0081,881,1771,971,6911,946,0712,007,2261,774,4411,534,9801,258,8361,169,5271,098,4711,290,8171,047,279934,4361,033,5451,061,085884,912685,237670,1161,100,6111,037,8351,160,5181,554,6901,490,2971,441,3391,390,1111,644,1251,517,1291,222,1301,038,4711,218,6631,064,6761,213,283828,3421,262,328833,303823,8241,017,730969,099723,311606,339585,132594,360564,616411,192307,930377,298288,363261,232078,8590114,262161,090
       Other Current Liabilities 
92,370
140,799
0
243,574
0
344,609
316,451
145,726
184,358
243,137
350,739
434,969
501,968
467,201
676,382
578,647
1,186,003
758,639
1,114,505
923,196
969,952
883,981
1,006,044
1,004,616
931,944
757,250
820,369
704,936
763,783
717,019
836,446
5,640,619
5,359,513
4,860,117
1,605,671
1,475,069
1,494,124
1,365,902
1,408,740
1,992,950
2,312,923
2,334,319
2,227,810
2,193,496
2,241,590
1,886,566
1,880,620
693,380
1,955,415
2,093,249
1,981,261
563,024
2,797,167
2,737,786
2,864,575
1,108,146
2,786,455
2,791,338
2,823,978
1,131,572
3,439,979
3,035,732
2,898,829
2,898,8293,035,7323,439,9791,131,5722,823,9782,791,3382,786,4551,108,1462,864,5752,737,7862,797,167563,0241,981,2612,093,2491,955,415693,3801,880,6201,886,5662,241,5902,193,4962,227,8102,334,3192,312,9231,992,9501,408,7401,365,9021,494,1241,475,0691,605,6714,860,1175,359,5135,640,619836,446717,019763,783704,936820,369757,250931,9441,004,6161,006,044883,981969,952923,1961,114,505758,6391,186,003578,647676,382467,201501,968434,969350,739243,137184,358145,726316,451344,6090243,5740140,79992,370
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,999,214
5,186,929
5,615,308
5,602,103
5,608,680
2,937,096
5,804,315
5,884,458
5,771,495
5,637,849
5,490,793
4,899,593
4,807,946
4,175,355
1,592,307
1,592,3074,175,3554,807,9464,899,5935,490,7935,637,8495,771,4955,884,4585,804,3152,937,0965,608,6805,602,1035,615,3085,186,9294,999,214000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,881,854
0
-5,817,037
-5,798,999
-3,201,451
-2,073,055
-742,461
-426,022
-85,428
-676,022
-1,925,757
-2,150,196
-1,336,062
-442,406
-1,897,706
0
0
57,612
52,691
0
50,877
56,535
66,512
0
0
0066,51256,53550,877052,69157,61200-1,897,706-442,406-1,336,062-2,150,196-1,925,757-676,022-85,428-426,022-742,461-2,073,055-3,201,451-5,798,999-5,817,0370-5,881,85400000000000000000000000000000000000000
> Total Stockholder Equity
166,593
345,607
346,072
584,580
587,440
1,885,090
2,080,090
2,311,363
2,382,456
2,473,292
2,666,954
3,041,781
3,134,110
3,376,292
3,628,143
4,084,553
4,204,075
4,455,722
4,911,295
5,531,006
5,609,138
5,762,547
6,238,940
6,963,107
7,049,953
7,424,515
7,880,888
8,711,274
8,856,280
9,159,519
9,290,078
10,292,786
10,325,355
10,647,582
10,800,657
8,987,895
9,142,389
9,203,220
6,591,114
6,580,872
6,722,951
6,118,947
6,379,515
6,846,767
7,244,495
7,681,812
7,596,224
7,427,820
7,603,217
7,921,201
8,017,368
7,974,108
8,683,450
8,939,256
9,330,741
9,634,187
9,860,748
10,134,893
10,594,803
10,072,226
10,381,269
10,778,067
10,920,883
10,920,88310,778,06710,381,26910,072,22610,594,80310,134,8939,860,7489,634,1879,330,7418,939,2568,683,4507,974,1088,017,3687,921,2017,603,2177,427,8207,596,2247,681,8127,244,4956,846,7676,379,5156,118,9476,722,9516,580,8726,591,1149,203,2209,142,3898,987,89510,800,65710,647,58210,325,35510,292,7869,290,0789,159,5198,856,2808,711,2747,880,8887,424,5157,049,9536,963,1076,238,9405,762,5475,609,1385,531,0064,911,2954,455,7224,204,0754,084,5533,628,1433,376,2923,134,1103,041,7812,666,9542,473,2922,382,4562,311,3632,080,0901,885,090587,440584,580346,072345,607166,593
   Common Stock
266,316
266,316
0
266,316
0
1,703,261
1,795,468
274,923
265,361
265,361
265,361
265,361
265,361
1,921,659
1,921,659
1,921,660
1,921,659
1,921,659
1,921,659
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,921,660
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,914,306
1,912,967
1,914,306
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,967
1,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,912,9671,914,3061,912,9671,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,914,3061,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6601,921,6591,921,6591,921,6591,921,6601,921,6591,921,659265,361265,361265,361265,361265,361274,9231,795,4681,703,2610266,3160266,316266,316
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000-1,574,098-1,464,497-749,905-1,660,094-1,657,060-1,657,060-1,658,443-1,656,086-1,285,766-1,108,981-621,541-578,955-468,688-311,151-247,385-74,394-84,142-71,000-74,343-74,621-160,350-157,523-158,012-159,952-163,932-264,082-104,189-96,477-63,333-59,351-48,578-73,898-49,826-26,288-60,118-69,415-64,816-73,951-42,641-41,157-37,717000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
772,356
0
476,396
742,050
772,100
559,478
52,426
865,510
676,469
97,673
424,832
532,635
546,889
52,380
711,096
670,543
600,389
-51,471
406,604
311,188
315,017
-133,427
-44,144
262,184
245,560
245,560262,184-44,144-133,427315,017311,188406,604-51,471600,389670,543711,09652,380546,889532,635424,83297,673676,469865,51052,426559,478772,100742,050476,3960772,35600000000000000000000000000000000000000



Balance Sheet

Currency in MXN. All numbers in thousands.




Cash Flow

Currency in MXN. All numbers in thousands.




Income Statement

Currency in MXN. All numbers in thousands.